Cord Blood News Volume 12.12 | Apr 2 2020

TOP STORY

The Intestinal Injury Caused by Ischemia‐Reperfusion Is Attenuated by Amniotic Fluid Stem Cells via the Release of Tumor Necrosis Factor‐Stimulated Gene 6 Protein

After ischemia/reperfusion-induced intestinal injury, amniotic fluid stem cells (AFSCs) migrated preferentially to the ileum, the primary site of injury, through blood circulation. Engrafted AFSCs reduced ileum injury, inflammation, and oxidative stress. [FASEB J] Full Article

(Ranked by impact factor of the journal)

Stable Cell Adhesion Affects Mesenchymal Stem Cell Sheet Fabrication: Effects of FBS and hPL

Human umbilical cord‐derived MSCs cultured in fetal bovine serum (FBS) and human platelet lysate (hPL) exhibited different actin cytoskeletal structures related to their cell morphologies and adhesion. MSCs cultured in FBS media showed stable cell adhesion on temperature responsive cell culture dishes with flattened cell shapes and aligned actin cytoskeletal structure. [J Tissue Eng Regen Med] Abstract

Hematogenous Donor Cell Routing Pathway after Transamniotic Stem Cell Therapy

Donor MSCs have been documented in fetal and maternal circulations after plain intra-amniotic injection, with diverse therapeutic effects. Scientists determined the pathway of this unique cell kinetic route. Rat fetuses were divided into two groups based on the content of intra-amniotic injections performed on gestational day 17: either a concentrated suspension of luciferase-labeled syngeneic amniotic fluid MSCs, or acellular luciferase. [Stem Cells Dev] Abstract

Efficient Cardiac Differentiation of Human Amniotic Fluid-Derived Stem Cells into Induced Pluripotent Stem Cells and Their Potential Immune Privilege

Researchers injected human amniotic fluid-derived stem cell-derived induced pluripotent stem cell-derived cardiomyocytes (hAFSC-iPSC-CMs) intramuscularly into rat infarcted hearts to evaluate the therapeutic potential of hAFSC-iPSC-CM transplantation. At day 21 of differentiation, the hAFSC-iPSC-CMs expressed cardiac-specific marker, presented cardiomyocyte-specific electrophysiological properties, and contracted spontaneously. [Int J Mol Sci] Full Article

Effect of CD44 on Differentiation of Human Amniotic Mesenchymal Stem Cells into Chondrocytes via Smad and ERK Signaling Pathways

The expression of chondrocyte-associated factors was detected in the absence and presence of the antibody blocker anti-CD44 antibody during the chondrogenic differentiation of human amniotic mesenchymal stem cells (hAMSCs). Following inhibition of CD44 expression, the transcriptional levels of chondrocyte‑associated genes SRY-box transcription factor 9, aggrecan and collagen type II α 1 chain, as well as the production of chondrocyte markers type II collagen and aggrecan were significantly decreased in hAMSCs. [Mol Med Rep] Abstract

Comparative Analysis of the Biosimilar and Innovative G-CSF Modulated Pathways on Umbilical Cord Blood–Derived Mononuclear Cells

The authors evaluated the transcriptomic changes in an in vitro model of umbilical cord blood cells (UBC) exposed to granulocyte colony-stimulating factor (G-CSF) for the identification of their modulated pathways. UBC-derived mononuclear cells were treated with biosimilar and innovator G-CSF for further gene expression profiling analysis using a microarray-based platform. [Bioinform Biol Insights] Full Article

Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News.

Inflammation in Myocardial Injury- Stem Cells as Potential Immunomodulators for Myocardial Regeneration and Restoration

Current implications of using MSCs owing to their immunomodulatory functions and paracrine effects could serve as an effective alternative treatment option for rejuvenating the heart post myocardial infarction. [Life Sci] Abstract | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Ryvu Therapeutics Receives Orphan Drug Designation from FDA for SEL120 to Treat Acute Myeloid Leukemia

Ryvu Therapeutics announced that the FDA has granted an orphan drug designation to Ryvu’s SEL120, for the treatment of patients with acute myeloid leukemia. [Ryvu Therapeutics] Press Release

AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

AVEO Oncology announced the discontinuation of their CyFi-2 study, a randomized Phase II clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). [AVEO Oncology] Press Release

Cull, Release or Bring Them Home: Coronavirus Crisis Forces Hard Decisions for Labs with Animals

As universities scale back operations and scientists observe stay-at-home orders, many are struggling to protect their research and the animals that power it. [Nature] Editorial

Universities Issue Hiring Freezes in Response to COVID-19

Numerous universities have made announcements about the suspension of hiring, including Miami University of Ohio, Wright State University, Villanova University, the University of Nevada, Reno, Indiana University, and the University of Auckland in New Zealand, which cites the travel ban affecting Chinese students as one of the main causes of its freeze. [The Scientist] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Positions – Leukemia (Temple University School of Medicine)

NEW Postdoctoral Position – Hematopoietic Stem Cells (Lund University)

Faculty Position – Regenerative Medicine (Guangzhou Regenerative Medicine and Health Guangdong Laboratory)

Postdoctoral Researcher – Hematologic Malignancies (Northwestern University)

Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Medical Center)

Postdoctoral Positions – Cancer Research (Moores Cancer Center, UC San Diego)

Team Leader – Clonal Evolution in Leukemias (Institute of Cancer Research)

Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden)

Postdoctoral Scientist – Stem Cell Biology (Cancer Research UK Manchester Institute)

Laboratory Director – Cord Blood Processing (PerkinElmer)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.